dc.contributor.authorDeng, Niantao
dc.contributor.authorGoh, Liang-Kee
dc.contributor.authorWang, Hannah
dc.contributor.authorDas, Kakoli
dc.contributor.authorTao, Jiong
dc.contributor.authorTan, Iain Beehuat
dc.contributor.authorZhang, Shenli
dc.contributor.authorLee, Minghui
dc.contributor.authorWu, Jeanie
dc.contributor.authorLim, Kiat Hon
dc.contributor.authorLei, Zhengdeng
dc.contributor.authorGoh, Glenn
dc.contributor.authorLim, Qing-Yan
dc.contributor.authorTan, Angie Lay-Keng
dc.contributor.authorPoh, Dianne Yu Sin
dc.contributor.authorRiahi, Sudep
dc.contributor.authorBell, Sandra
dc.contributor.authorShi, Michael M.
dc.contributor.authorLinnartz, Ronald
dc.contributor.authorZhu, Feng
dc.contributor.authorYeoh, Khay Guan
dc.contributor.authorToh, Han Chong
dc.contributor.authorYong, Wei Peng
dc.contributor.authorCheong, Hyun Cheol
dc.contributor.authorRha, Sun Young
dc.contributor.authorBoussioutas, Alex
dc.contributor.authorGrabsch, Heike
dc.contributor.authorRozen, Steve G.
dc.contributor.authorTan, Patrick
dc.date.accessioned2013-10-07T04:03:30Z
dc.date.available2013-10-07T04:03:30Z
dc.date.copyright2012
dc.date.issued2012
dc.identifier.citationDeng, N., Goh, L.-K., Wang, H., Das, K., Tao, J., Tan, I. B., et al. (2012). A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut, 61(5).
dc.identifier.urihttp://hdl.handle.net/10220/16299
dc.description.abstractObjective Gastric cancer is a major gastrointestinal malignancy for which targeted therapies are emerging as treatment options. This study sought to identify the most prevalent molecular targets in gastric cancer and to elucidate systematic patterns of exclusivity and co-occurrence among these targets, through comprehensive genomic analysis of a large panel of gastric cancers. Design Using high-resolution single nucleotide polymorphism arrays, copy number alterations were profiled in a panel of 233 gastric cancers (193 primary tumours, 40 cell lines) and 98 primary matched gastric non-malignant samples. For selected alterations, their impact on gene expression and clinical outcome were evaluated. Results 22 recurrent focal alterations (13 amplifications and nine deletions) were identified. These included both known targets (FGFR2, ERBB2) and also novel genes in gastric cancer (KLF5, GATA6). Receptor tyrosine kinase (RTK)/RAS alterations were found to be frequent in gastric cancer. This study also demonstrates, for the first time, that these alterations occur in a mutually exclusive fashion, with KRAS gene amplifications highlighting a clinically relevant but previously underappreciated gastric cancer subgroup. FGFR2-amplified gastric cancers were also shown to be sensitive to dovitinib, an orally bioavailable FGFR/VEGFR targeting agent, potentially representing a subtype-specific therapy for FGFR2-amplified gastric cancers. Conclusion The study demonstrates the existence of five distinct gastric cancer patient subgroups, defined by the signature genomic alterations FGFR2 (9% of tumours), KRAS (9%), EGFR (8%), ERBB2 (7%) and MET (4%). Collectively, these subgroups suggest that at least 37% of gastric cancer patients may be potentially treatable by RTK/RAS directed therapies.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesGuten_US
dc.subjectDRNTU::Science::Biological sciences
dc.titleA comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targetsen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.identifier.doihttp://dx.doi.org/10.1136/gutjnl-2011-301839


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record